抗体介导的排斥反应在器官移植中的研究进展  

Antibody-mediated rejection in organ transplantation:research progress

作　　者：刘浩 宋少华[1] 杨璟辉[1] 倪之嘉[1] 傅志仁[1] LIU Hao;SONG Shao-hua;YANG Jing-hui;NI Zhi-jia;FU Zhi-ren(Department of Organ Transplantation,Changzheng Hospital,Naval Medical University(Second Military Medical University),Shanghai 200003,China)

机构地区：[1]海军军医大学(第二军医大学)长征医院器官移植科,上海200003

出　　处：《第二军医大学学报》2021年第11期1284-1289,共6页Academic Journal of Second Military Medical University

基　　金：国家自然科学基金(81801590,81970563)。

摘　　要：器官移植是各种终末期疾病的最终治疗手段,新型免疫抑制剂的应用使细胞性排斥反应得到有效控制,而体液性排斥反应即供体特异性抗体介导的排斥反应仍是造成移植失败甚至受体死亡的重要因素。抗体介导的排斥反应在超急性排斥反应和慢性排斥反应的发生、发展中起着重要作用,但目前医学界对抗体介导的排斥反应的认识还很有限。本文就抗体介导的排斥反应的发生机制、检测与治疗等方面进行综述。Organ transplantation is the ultimate treatment for various end-stage diseases,and cellular rejection has been effectively controlled due to the application of new immunosuppressants.However,humoral rejection,that is,the rejection mediated by donor-specific antibodies,is still an important factor leading to graft failure or even death of recipients.Antibody-mediated rejection plays a significant role in the development and progression of hyperacute rejection and chronic rejection,but the understanding is still limited in the medical community.This article reviews the mechanism,detection and treatment of antibody-mediated rejection.

关 键 词：器官移植 供体特异性抗体 体液性排斥反应 抗体介导的排斥反应 发生机制 检测 治疗 

分 类 号：R392.4[医药卫生—免疫学]